Highly Regioselective Palladium-Catalyzed Direct Arylation of Oxazole at C-2 or C-5 with Aryl Bromides, Chlorides, and Triflates
作者:Neil A. Strotman、Harry R. Chobanian、Yan Guo、Jiafang He、Jonathan E. Wilson
DOI:10.1021/ol1011778
日期:2010.8.20
Complementary palladium-catalyzed methods for directarylation of oxazole with high regioselectivity (>100:1) at both C-5 and C-2 have been developed for a wide range of aryl and heteroaryl bromides, chlorides, iodides, and triflates. C-5 arylation is preferred in polar solvents with phosphines 5 or 6, whereas C-2 arylation is preferred by nonpolar solvents and phosphine 3. This represents the first
Solution-phase parallel oxazole synthesis with TosMIC
作者:Bheemashankar A. Kulkarni、A. Ganesan
DOI:10.1016/s0040-4039(99)01050-3
日期:1999.7
A quaternary ammonium hydroxide ion exchange resin catalyzes the reaction of p-tolylsulfonylmethyl isocyanide (TosMIC) with aromatic aldehydes to give 5-aryloxazoles. The base and the p-tolylsulfinic acid byproduct are removed by simple filtration, resulting in oxazoles in high yield and purity.
streptochlorin analogues in which indole has been replaced by other heterocycles has been designed and synthesized, as a continuation of our studies aimed at the discovery of novel streptochlorin analogues with improved antifungalactivity. Biological testing showed that most of the indole-replaced streptochlorin analogues were inactive, though compound 6f had a broad spectrum of antifungalactivity with significant
PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
申请人:Schering Corporation
公开号:EP2178867A1
公开(公告)日:2010-04-28
[EN] PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF<br/>[FR] PROCÉDÉ DE PRODUCTION DE 5-QUINOLYL-OXAZOLES SUBSTITUÉS ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI
申请人:SCHERING CORP
公开号:WO2009009003A1
公开(公告)日:2009-01-15
The present invention relates a process for the preparation of a compound of the following formula, wherein R1, R2, R6, R9 and R10 are as described herein. The compounds are inhibitors of phosphodiesterase 4 (PDE4).